Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $28.2 million.

  • Apellis Pharmaceuticals' Share-based Compensation rose 258.78% to $28.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $109.1 million, marking a year-over-year decrease of 435.14%. This contributed to the annual value of $114.1 million for FY2024, which is 772.38% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Share-based Compensation of $28.2 million as of Q3 2025, which was up 258.78% from $27.2 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Share-based Compensation registered a high of $30.3 million during Q1 2024, and its lowest value of $16.4 million during Q1 2021.
  • In the last 5 years, Apellis Pharmaceuticals' Share-based Compensation had a median value of $26.2 million in 2023 and averaged $24.5 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Share-based Compensation skyrocketed by 7687.76% in 2021, and later crashed by 980.26% in 2025.
  • Apellis Pharmaceuticals' Share-based Compensation (Quarter) stood at $19.3 million in 2021, then rose by 25.52% to $24.2 million in 2022, then rose by 8.16% to $26.2 million in 2023, then rose by 0.36% to $26.3 million in 2024, then grew by 7.11% to $28.2 million in 2025.
  • Its Share-based Compensation stands at $28.2 million for Q3 2025, versus $27.2 million for Q2 2025 and $27.4 million for Q1 2025.